Akari Therapeutics announces 1-for-40 reverse ADS ratio change to meet Nasdaq bid price requirement

Akari Therapeutics Plc

ADS ratio changes from 1:2,000 to 1:80,000 ordinary shares; each 40 current ADSs become 1 new ADS effective March 31, 2026.
No change to underlying ordinary shares; fractional ADSs will be aggregated and sold with cash proceeds distributed.
Action intended to maintain compliance with Nasdaq minimum bid price requirement for continued listing.
Trading continues on Nasdaq under symbol AKTX; Deutsche Bank will handle the exchange.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.